echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Ma Liu Consensus: Flow chart of empiric Hp eradication treatment

    Ma Liu Consensus: Flow chart of empiric Hp eradication treatment

    • Last Update: 2022-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    The 6th Edition Maastricht/Florence Consensus 2021 report covers advances in the management of Helicobacter pylori (Hp) infection, providing guidance on the management of Hp infection and recommending
    eradication therapies for treatment of Hp infection.

    Click to view details: Which eradication therapies are recommended by the Ma Liu Consensus? Management of Helicobacter pylori infection - Maastricht VI/Florence Consensus Report Released!

    The consensus states that hp is empirically eradicated if individual antibiotic susceptibility tests are not possible

    The following is a flowchart of empiric eradication hp therapy:

    Bismuth quadruple therapy: proton pump inhibitors (PPIs), bismuth agents, tetracycline, and metronidazole

    Clarithromycin triple therapy: PPI, clarithromycin, and amoxicillin (used only when locally proven effective or known sensitivity to clarithromycin) non-bismuth quadruple therapy (with accompaniment) :P PI, clarithromycin, amoxicillin, and metronidazole

    Levofloxacin tetratherapy: PPI, levofloxacin, amoxicillin, and bismuth.

    Levofloxacin triple therapy: same as above, but without bismuth

    In the case of high fluoroquinolone resistance (> 15%), bismuth may be selected in combination with other antibiotics or high-dose PPI-amoxicillin diptych or rifabutin

    *High dose PPI or potassium ion competitive acid blocker (P-CAB) (vonoracin, if available) plus amoxicillin may be used as an alternative

    References: Malfertheiner P, Megraud F, Rokkas T, et al.
    Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report[J].
    Gut, 2022, 71(9): 1724-1762.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.